Real ‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

ConclusionThe effectiveness of palbociclib and endocrine therapy in the treatment of HR-positive, HER2-negative mBC in the real-world setting is similar to the efficacy reported in the PALOMA-2 trial. Patients with lower neutrophil count may have a lower risk of early disease progression.

Source: Cancer Medicine - September 30, 2021 Category: Cancer & Oncology Authors: James Sun, Xiaojun Zhong, Junjie Ma, Weihong Sun, Hyo S. Han, Hatem H. Soliman, Loretta S. Loftus, Ricardo L. B. Costa, Avan J. Armaghani, Aixa E. Soyano ‐Muller, Brian J. Czerniecki, M. Catherine Lee, John V. Kiluk, Nazanin Khakpour, Susa Tags: RESEARCH ARTICLE Source Type: research